 |
|
 |
Izvorni znanstveni članak
https://doi.org/10.11613/BM.2015.027
Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery
Stanislava Petrovic
; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Natasa Bogavac-Stanojevic
; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Dragana Lakic
; Department of Social Pharmacy and Pharmacy Legislation, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Amira Peco-Antic
; School of Medicine, University of Belgrade, Belgrade, Serbia
Irena Vulicevic
; Department of Nephrology, University Children’s Hospital, Belgrade, Serbia
Ivana Ivanisevic
; Department of Nephrology, University Children’s Hospital, Belgrade, Serbia
Jelena Kotur-Stevuljevic
; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
Zorana Jelic-Ivanovic
; Department of Medical Biochemistry, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia
| Puni tekst: engleski, pdf (294 KB) | str. 262-271 | citiraj | |
|
APA 6th Edition Petrovic, S., Bogavac-Stanojevic, N., Lakic, D., Peco-Antic, A., Vulicevic, I., Ivanisevic, I., ... Jelic-Ivanovic, Z. (2015). Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochemia Medica, 25 (2), 262-271. https://doi.org/10.11613/BM.2015.027 MLA 8th Edition Petrovic, Stanislava, et al. "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery." Biochemia Medica, vol. 25, br. 2, 2015, str. 262-271. https://doi.org/10.11613/BM.2015.027. Citirano 27.01.2021. Chicago 17th Edition Petrovic, Stanislava, Natasa Bogavac-Stanojevic, Dragana Lakic, Amira Peco-Antic, Irena Vulicevic, Ivana Ivanisevic, Jelena Kotur-Stevuljevic i Zorana Jelic-Ivanovic. "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery." Biochemia Medica 25, br. 2 (2015): 262-271. https://doi.org/10.11613/BM.2015.027 Harvard Petrovic, S., et al. (2015). 'Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery', Biochemia Medica, 25(2), str. 262-271. https://doi.org/10.11613/BM.2015.027 Vancouver Petrovic S, Bogavac-Stanojevic N, Lakic D, Peco-Antic A, Vulicevic I, Ivanisevic I i sur. Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochemia Medica [Internet]. 2015 [pristupljeno 27.01.2021.];25(2):262-271. https://doi.org/10.11613/BM.2015.027 IEEE S. Petrovic, et al., "Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery", Biochemia Medica, vol.25, br. 2, str. 262-271, 2015. [Online]. https://doi.org/10.11613/BM.2015.027 |
|||
Sažetak
Introduction: Acute kidney injury (AKI) is significant problem in children with congenital heart disease (CHD) who undergo cardiac surgery. The economic impact of a biomarker-based diagnostic strategy for AKI in pediatric populations undergoing CHD surgery is unknown. The aim of this study was to perform the cost effectiveness analysis of using serum cystatin C (sCysC), urine neutrophil gelatinase-associated lipocalin (uNGAL) and urine liver fatty acid-binding protein (uL-FABP) for the diagnosis of AKI in children after cardiac surgery compared with current diagnostic method (monitoring of serum creatinine (sCr) level).
Materials and methods: We developed a decision analytical model to estimate incremental cost-effectiveness of different biomarker-based diagnostic strategies compared to current diagnostic strategy. The Markov model was created to compare the lifetime cost associated with using of sCysC, uNGAL, uL-FABP with monitoring of sCr level for the diagnosis of AKI. The utility measurement included in the analysis was quality-adjusted life years (QALY). The results of the analysis are presented as the incremental cost-effectiveness ratio (ICER).
Results: Analysed biomarker-based diagnostic strategies for AKI were cost-effective compared to current diagnostic method. However, uNGAL and sCys C strategies yielded higher costs and lower effectiveness compared to uL-FABP strategy. uL-FABP added 1.43 QALY compared to current diagnostic method at an additional cost of $8521.87 per patient. Therefore, ICER for uL-FABP compared to sCr was $5959.35/QALY.
Conclusions: Our results suggest that the use of uL-FABP would represent cost effective strategy for early diagnosis of AKI in children after cardiac surgery.
Ključne riječi
acute kidney injury; cardiac surgery; children; biomarkers; cost effectiveness analysis
Hrčak ID: 139813
URI
https://hrcak.srce.hr/139813
Moj profil
Srce